Last updated: May 24, 2026
MOXATAG is the brand for extended-release oral amoxicillin (active ingredient: amoxicillin) tablets used for pediatric acute bacterial otitis media and adult acute bacterial sinusitis (FDA-labeled indications). Current public disclosure is not sufficient to produce a complete, citation-backed clinical-trials update, market sizing, and competitive projection for MOXATAG under the required data-density and sourcing constraints.
What clinical trials exist for MOXATAG and where are they in 2026?
No complete, source-citable set of MOXATAG-specific trial records, enrollment status, endpoints, and timelines is available in the provided context. Without verifiable trial identifiers (eg, NCT numbers), phase breakdown, and last-updated dates, a faithful clinical update cannot be compiled.
Which MOXATAG indications have active or completed studies?
A definitive indication-level inventory (otitis media vs sinusitis vs any off-label or additional label expansion) requires MOXATAG-specific clinical registries and label history references that are not present here.
What endpoints and comparators did MOXATAG trials use?
Endpoint detail (time to response, microbiologic eradication, non-inferiority margins, resistance sub-studies) must be traced to trial protocols and results publications, which are not included in the available material.
How big is the MOXATAG market and what’s the revenue projection through exclusivity?
A quantified market model requires (1) current and historical US prescription volumes, (2) pricing or net sales data, (3) share by antibiotic class, (4) payer mix and channel mix, and (5) adoption drivers tied to the labeled regimen. None of these inputs are provided in the available context, and a citation-backed model cannot be produced.
What drives MOXATAG demand (formulation, dosing adherence, guideline fit)?
Mechanistic adoption factors (once-daily extended release vs standard amoxicillin schedules) can influence formulary placement, but a business-grade projection requires public claims, formulary evidence, or market access disclosures that are not present here.
How is MOXATAG positioned versus immediate-release amoxicillin and other β-lactams?
A defensible competitive positioning table needs current competitor mix (amoxicillin IR, amoxicillin-clavulanate ER/IR, cephalosporins, macrolides, and local guideline-based usage) with cited shares or utilization metrics. Those inputs are not available here.
What patents protect MOXATAG and how strong is the patent estate for exclusivity?
A patent-structure answer needs MOXATAG Orange Book listings (patent numbers, expiration dates, exclusivity codes) and any relevant Orange Book “method of use,” “formulation,” and “manufacturing” patents tied to the NDA. None of that Orange Book listing data is included in the provided context.
What is the Orange Book status of MOXATAG (listed patents, expiration dates, exclusivity)?
Orange Book status cannot be stated without the NDA number and its listed patent/exclusivity data.
When does MOXATAG lose exclusivity in the US?
A US exclusivity timeline requires the NDA’s exclusivity start and end dates (including any pediatric exclusivity extensions) and the last patent expiry. This data is not available in the provided context.
What generic entry risks exist for MOXATAG (Paragraph IV and authorized generics)?
Paragraph IV risk assessment requires: potential ANDA filers and their certifications (IV vs I vs II), notice-of-certification dates, and litigation or settlement disclosures. None of these are available here.
Which companies are challenging MOXATAG?
A named-challenger list requires publicly filed ANDA/Paragraph IV case data tied to the MOXATAG reference product.
What patent litigation affects MOXATAG and what settlements are known?
Litigation timelines (complaint filing dates, claim construction orders, stay/scoping orders, settlement effective dates) require docket-level sources not present here.
What formulations and manufacturing methods are protected for MOXATAG?
Formulation and process barrier analysis depends on claim-level review of listed formulation/manufacturing patents (polymer matrices, osmotic release systems, coating systems, strength-specific compositions, and manufacturing controls). No patent documents or claim sets are provided.
How does MOXATAG compare with other amoxicillin extended-release products?
A side-by-side comparison requires specific comparator brands with comparable strengths, dosing schedules, and FDA labeling language, plus their respective patent/market positions. No comparator list or referenced data is available here.
What is the FDA regulatory status of MOXATAG (NDA, approvals, label milestones)?
Regulatory status requires NDA/ANDA references, approval dates, supplement history, and any FDA labeling updates tied to efficacy and safety. None of those identifiers are included in the provided context.
Key Takeaways
- A citation-backed clinical trials update for MOXATAG cannot be produced without MOXATAG-specific trial identifiers and results timelines.
- A quantified market analysis and revenue projection cannot be produced without prescription and net sales/price inputs and share benchmarks.
- Patent, exclusivity, and generic-entry risk cannot be assessed without Orange Book listing data tied to the MOXATAG NDA and without Paragraph IV/litigation filings.
FAQs
- What is MOXATAG’s current FDA label and which indications are approved?
- Are there any MOXATAG NCT-listed trials with published results, and what were the outcomes?
- What is the MOXATAG Orange Book NDA number and what patents are listed against it?
- Have any ANDAs filed for MOXATAG, and are there any Paragraph IV notices or settlements?
- How does MOXATAG’s once-daily extended-release regimen affect antibiotic adherence versus immediate-release amoxicillin?
References
No sources are cited because the provided context contains no verifiable MOXATAG clinical, regulatory, patent, or market data.
